1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) – Forecasts To 2017

Patent expiry of major blockbuster drugs is a prime concern for pharmaceutical companies, as developing a new chemical entity (NCE) is more expensive and time consuming than a novel drug delivery technology. Therefore, in recent years, several pharmaceutical companies have employed drug delivery technology as a life cycle management tool for some of their blockbuster drugs, the patents for which are set to expire in the near future.
The North American drug delivery market was estimated to be worth $66.7 billion in 2012, and is expected to register a CAGR of 8.9% between 2012 and 2017. Based on the route of administration, the drug delivery market has been classified as oral, pulmonary, injectable, transdermal, implantable, ocular, nasal, transmucosal, and topical. In 2012, oral drug delivery segment dominated the market with a share of approximately 38%, followed by pulmonary drug delivery segment with a 20% share.


The drug delivery technologies that have recently gained importance in the North American market include orodispersible tablet (ODT), dry powder inhalers, transdermal patches, needle-free injectors, auto and pen injectors, and buccal transmucosal tablets; controlled release is the most widely accepted technology. The use of implantable devices for drug delivery is also on a rise.


Big pharmaceutical companies such as Pfizer and Merck have established in-house capabilities for the development of drug delivery technologies. On the contrary, many other companies are still relying on specialty companies engaged in the development of drug delivery technologies. High level of competition and increasing need for outsourcing has resulted in the drug delivery market to be fragmented, with several small companies developing novel drug delivery technologies for niche therapeutic applications.


The North American drug delivery market is largely dominated by the U.S. (accounting for about 89% of the overall market). The key drivers for the U.S. drug delivery market are the well established pharmaceutical industry , healthcare reforms, and favourable changes in the FDA review process. Factors such as low cost drug manufacturing and rising number of drug delivery formulations and devices are propelling the Canadian market.


Key players in the drug delivery technologies market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton, Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), The Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.) and Valeant Pharmaceuticals (Canada).


Scope of the report:


This research report categorizes and analyzes the North American Drug Delivery Technologies market on the basis of routes of administration. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S and Canada), to provide in-depth information on the North American market scenario.

North American drug delivery technologies market, by segment:

Oral Drug Delivery
Controlled Release
Orodispersible Tablets (ODT) and Taste Masking
Others
Pulmonary Drug Delivery
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Transdermal Drug Delivery
Passive Drug Delivery
Reservoir System
Matrix System
Active Drug Delivery
Iontophoresis
Microporation
Others
Injectable Drug Delivery
Conventional Injection Devices
Fillable Syringes
Prefilled Syringes
Self-injection Devices
Needle-free Injectors
Auto-injectors or Safety Syringe Devices
Pen Injectors
Others
Ocular Drug Delivery
Eye Drops
Ointment and Gel
Others
Nasal Drug Delivery
Nasal Drops
Nasal Sprays
Nasal Inhalers
Others
Topical Drug Delivery
Liquid Formulations
Semisolid Formulations
Solid Formulations
Implantable Drug Delivery
Drug-Eluting Stents
Implantable Infusion Pumps
Contraceptive Implants
Intravitreal Implants
Brachytherapy Seeds
Transmucosal Drug Delivery
Oral (Buccal and Sublingual)
Others (Rectal and Vaginal)

North America drug delivery technologies market, by country:

U.S
Canada

Table Of Contents

North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 2017
1 INTRODUCTION 22
1.1 KEY TAKE-AWAYS 22
1.2 REPORT DESCRIPTION 22
1.3 MARKETS COVERED 24
1.4 STAKEHOLDERS 26
1.5 RESEARCH METHODOLOGY 26
1.5.1 MARKET SIZE 26
1.5.2 MARKET SHARE 27
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 27
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 28
1.5.5 ASSUMPTIONS 28
2 EXECUTIVE SUMMARY 29
3 MARKET OVERVIEW 33
3.1 INTRODUCTION 34
3.2 MARKET SEGMENTATION 34
3.3 MARKET DYNAMICS 36
3.3.1 DRIVERS 36
3.3.1.1 Patent Cliff and Increased Competition to Increase Adoption Rate 36
3.3.1.2 Improving Patient Compliance and Acceptability, An Impetus to the Drug Delivery Systems Market 37
3.3.1.3 Increasing Focus on Pediatric and Geriatric Patients to Boost the Growth 38
3.3.1.4 Increasing Incidence of Chronic Diseases in North America to Enhance Demand 38
3.3.2 RESTRAINTS 39
3.3.2.1 Drug Failures and Recalls Mar Market Growth 39
3.3.2.2 Technical Barriers Restrict Growth 40

3.3.3 OPPORTUNITIES 41
3.3.3.1 Collaborations Between Pharmaceutical Companies and Drug Delivery Firms 41
3.3.3.2 Self-administration and Home Care Drug Delivery Devices 42
3.3.3.3 Expanding therapeutic applications of drug delivery technologies 43
3.3.4 TARGETED DRUG DELIVERY 43
3.3.4.1 Passive Systems Contribute 60% to the Targeted Drug Delivery Market 44
3.3.4.2 Active Targeted Drug Delivery has Major Applications in Cancer Therapy 44
3.3.4.3 Companies Focus on Novel Targeted Drug Delivery 44
3.3.5 BURNING ISSUES 45
3.3.5.1 Striking Right Partnerships 45
3.3.5.2 Improving the Bioavailability of Drugs 46
3.4 REGULATORY ENVIRONMENT 47
3.4.1 STRINGENT REGULATIONS FOR PHARMACEUTICAL DRUGS IN NORTH AMERICA 47
3.4.1.1 The Approval Process is Complex, Time-consuming, and Expensive 47
3.4.2 EFFECT OF THE U.S. HEALTHCARE REFORMS ON THE DRUG DELIVERY INDUSTRY 48
3.4.2.1 Drug Delivery Companies to Benefit from the Affordable Care Act (ACA) Reform in the Long Run 48
3.4.3 REGULATIONS RELATED TO THE APPROVAL OF CONTROLLED RELEASE DRUGS 48
3.5 PORTER'S FIVE FORCES ANALYSIS 49
3.5.1 THREAT OF NEW ENTRANTS 50
3.5.2 THREAT OF SUBSTITUTES 50
3.5.3 COMPETITOR'S RIVALRY 50
3.5.4 BARGAINING POWER OF SUPPLIERS 51
3.5.5 BARGAINING POWER OF BUYERS 51
3.6 VALUE CHAIN ANALYSIS 52
3.7 MARKET SHARE ANALYSIS 53
3.7.1 PULMONARY DRUG DELIVERY 53
3.7.1.1 U.S. 53
3.7.1.2 Canada 55
3.7.2 TRANSDERMAL DRUG DELIVERY 55
3.7.2.1 U.S. 55
3.7.2.2 Canada 57
3.7.3 INECTABLE DRUG DELIVERY DEVICES 58
3.7.3.1 U.S. 58
3.7.3.2 Canada 60
3.7.4 IMPLANTABLE DRUG DELIVERY 61
3.7.4.1 U.S. 61
3.7.4.2 Canada 62
3.7.5 OTHER DRUG DELIVERY SEGMENTS 63
4 NORTH AMERICA DRUG DELIVERY MARKET, BY TECHNOLOGY 65
4.1 INTRODUCTION 66
4.1.1 DRUG DELIVERY MARKET WITNESSING TECHNOLOGICAL ADVANCEMENTS 66
4.2 OPPORTUNITY MATRIX 68
4.3 ORAL DRUG DELIVERY 70
4.3.1 REFORMULATION STRATEGIES and ESTABLISHING IN-HOUSE CAPABILITIES HELP IN SIGNIFICANT GROWTH 70
4.3.2 CONTROLLED RELEASE 72
4.3.3 ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING 75
4.3.4 OTHERS 76
4.4 PULMONARY DRUG DELIVERY 78
4.4.1 THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY 79
4.4.1.1 Application of pulmonary delivery for non-respiratory therapies is a growing opportunity 79
4.4.2 METERED DOSE INHALERS (MDI) 82
4.4.3 DRY POWDER INHALERS (DPI) 83
4.4.4 NEBULIZERS 84
4.5 TRANSDERMAL DRUG DELIVERY 86
4.5.1 PASSIVE TRANSDERMAL DRUG DELIVERY 88
4.5.1.1 Matrix system 90
4.5.1.2 Reservoir system 90
4.5.2 ACTIVE TRANSDERMAL DRUG DELIVERY 91
4.5.2.1 Microporation 92
4.5.2.2 Iontophoresis 93
4.5.2.3 Others 93
4.6 INJECTABLE DRUG DELIVERY 94
4.6.1 INJECTABLE DRUG DELIVERY MARKET WITNESSING DEVELOPMENTS RELATED TO PRODUCT IMPROVEMENT 94
4.6.2 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 97
4.6.2.1 Low manufacturing cost and affordable prices: key driver for conventional injection devices 97
4.6.2.2 Fillable 99
4.6.2.3 Prefilled 100
4.6.3 SELF-INJECTION DEVICES 100
4.6.3.1 Self-injection devices reduce overall treatment cost 101
4.6.3.2 Pen injectors 103
4.6.3.3 Needle-free injectors 104
4.6.3.4 Auto injectors 105
4.6.4 OTHERS 106
4.7 OCULAR DRUG DELIVERY 108
4.7.1 EYE DROPS 110
4.7.2 OINTMENTS AND GELS 111
4.7.3 OTHERS 112
4.8 NASAL DRUG DELIVERY 114
4.8.1 NASAL DRUG DELIVERY PREFERRED FOR LOCALLY ACTING DRUGS AND DELIVERY OF VACCINES 114
4.8.2 NASAL SPRAYS 116
4.8.3 NASAL INHALERS 118
4.8.4 NASAL DROPS 119
4.8.5 OTHERS 120
4.9 TOPICAL DRUG DELIVERY 121
4.9.1 TOPICAL DELIVERY MAJORLY ADOPTED FOR DERMATOLOGY DRUGS 121
4.9.2 SEMI-SOLID FORMULATIONS 124
4.9.3 LIQUID FORMULATIONS 125
4.9.4 SOLID FORMULATIONS 126
4.10 IMPLANTABLE DRUG DELIVERY 128
4.10.1 DRUG- ELUTING STENTS 130
4.10.2 IMPLANTABLE INFUSION PUMPS 132
4.10.2.1 Implantable infusion pumps largely used for therapies of chronic ailments 133
4.10.3 CONTRACEPTIVE IMPLANTS 134
4.10.4 INTRAVITREAL IMPLANTS 134
4.10.5 BRACHYTHERAPY SEEDS 136
4.11 TRANSMUCOSAL DRUG DELIVERY 138
4.11.1 ORAL (BUCCAL AND SUBLINGUAL) 140
4.11.2 OTHERS (RECTAL, VAGINAL) 142
5 GEOGRAPHIC ANALYSIS 144
5.1 INTRODUCTION 145
5.2 UNITED STATES 147
5.2.1 WELL-ESTABLISHED U.S. PHARMACEUTICAL INDUSTRY DRIVES THE DRUG DELIVERY MARKET 147
5.2.2 FAVORABLE CHANGES IN THE FDA TO ACCELERATE DRUG REVIEW AND APPROVAL PROCESSES 148
5.2.3 U.S. HEALTHCARE REFORMS WILL IMPACT THE DRUG DELIVERY MARKET 148
5.3 CANADA 159
5.3.1 INSURANCE COVERAGE FAVORING THE GROWTH OF CANADIAN DRUG DELIVERY TECHNOLOGY MARKET 159
5.3.2 RISE IN NUMBER OF APPROVALS AND AGREEMENTS IN THE CANADA DRUG DELIVERY MARKET 159
6 COMPETITIVE LANDSCAPE 171
6.1 INTRODUCTION 171
6.1.1 MERGERS and ACQUISITIONS AND AGREEMENTS and COLLABORATIONS WERE THE KEY STRATEGIES ADOPTED BY PLAYERS 172
6.2 MERGERS and ACQUISITIONS 172
6.3 AGREEMENTS, COLLABORATIONS, JOINT VENTURES and PARTNERSHIPS 175
6.4 NEW PRODUCT LAUNCH 177
6.5 OTHER DEVELOPMENTS 179
7 COMPANY PROFILES 187
(Overview, Financials, Products and Services, Strategy, and Developments)*
7.1 3M COMPANY 187
7.2 APTALIS PHARMA, INC. 194
7.3 BAXTER INTERNATIONAL, INC. 199
7.4 BECTON, DICKINSON AND COMPANY 205
7.5 CATALENT PHARMA SOLUTIONS 212
7.6 CIMA LABS 219
7.7 ENDO HEALTH SOLUTIONS, INC. 225
7.8 JOHNSON and JOHNSON, INC. 231
7.9 NEKTAR THERAPEUTICS, INC. 238
7.10 OPTINOSE AS 242
7.11 PSIVIDA CORPORATION 246
7.12 THE DOW CHEMICAL COMPANY 251
7.13 VALEANT PHARMACEUTICALS 257
*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.


LIST OF TABLES


TABLE 1 NORTH AMERICA DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 31
TABLE 2 KEY DRUG DELIVERY TECHNOLOGY PROVIDERS and MARKETER COMPANIES 63
TABLE 3 NORTH AMERICAN DRUG DELIVERY MARKET,
BY ROUTE OF ADMINISTRATION, 2010 - 2017 67
TABLE 4 NORTH AMERICAN ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 71
TABLE 5 NORTH AMERICAN ORAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 72
TABLE 6 CONTROLLED RELEASE DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 74
TABLE 7 ODT and TASTE-MASKING MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 76
TABLE 8 OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 77
TABLE 9 NORTH AMERICAN PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 80
TABLE 10 NORTH AMERICAN PULMONARY DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 81
TABLE 11 COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES 81
TABLE 12 METERED DOSE INHALATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 83
TABLE 13 DRY POWDER INHALATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 84
TABLE 14 NEBULIZERS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 85
TABLE 15 NORTH AMERICAN TRANSDERMAL DRUG DELIVERY MARKET,
BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 87
TABLE 16 NORTH AMERICAN TRANSDERMAL DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 88
TABLE 17 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 89
TABLE 18 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 90
TABLE 19 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 91
TABLE 20 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 92
TABLE 21 NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 - 2017 ($BILLION) 95
TABLE 22 NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($BILLION) 96
TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,
2010 - 2017 ($BILLION) 98
TABLE 24 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY,
2010 - 2017 ($BILLION) 99
TABLE 25 SELF-INJECTION DEVICES MARKET, BY PRODUCT,
2010 - 2017 ($MILLION) 102
TABLE 26 SELF-INJECTION DEVICES MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 103
TABLE 27 OTHER INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 107
TABLE 28 NORTH AMERICAN OCULAR DRUG DELIVERY MARKET,
BY FORMULATION, 2010 - 2017 ($MILLION) 109
TABLE 29 NORTH AMERICAN OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 110
TABLE 30 EYE DROP DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 111
TABLE 31 OINTMENT and GEL DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 112
TABLE 32 OTHER OCULAR DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 113
TABLE 33 NORTH AMERICAN NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION) 115
TABLE 34 NORTH AMERICAN NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 116
TABLE 35 NASAL SPRAY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 117
TABLE 36 NASAL INHALER MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 118
TABLE 37 NASAL DROPS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 119
TABLE 38 OTHER NASAL DELIVERY FORMULATIONS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 120
TABLE 39 NORTH AMERICAN TOPICAL DRUG DELIVERY MARKET,
BY FORMULATION, 2010 - 2017 ($MILLION) 123
TABLE 40 NORTH AMERICAN TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 124
TABLE 41 SEMI-SOLID TOPICAL FORMULATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 125
TABLE 42 LIQUID TOPICAL FORMULATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 126
TABLE 43 SOLID TOPICAL FORMULATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 127
TABLE 44 NORTH AMERICAN IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE, 2010 - 2017 ($MILLION) 129
TABLE 45 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 130
TABLE 46 DRUG-ELUTING STENTS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 132
TABLE 47 IMPLANTABLE INFUSION PUMPS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 133
TABLE 48 CONTRACEPTIVE IMPLANTS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 134
TABLE 49 INTRAVITREAL IMPLANTS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 135
TABLE 50 BRACHYTHERAPY SEEDS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 137
TABLE 51 NORTH AMERICAN TRANSMUCOSAL DRUG DELIVERY MARKET,
BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 139
TABLE 52 NORTH AMERICAN TRANSMUCOSAL DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 140
TABLE 53 ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 141
TABLE 54 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 142
TABLE 55 NORTH AMERICAN DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 146
TABLE 56 U.S.: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 149
TABLE 57 U.S.: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 150
TABLE 58 NORTH AMERICAN PULMONARY DRUG DELIVERY MARKET,
BY DEVICE TYPE, 2010 - 2017 ($MILLION) 151
TABLE 59 U.S.: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 152
TABLE 60 U.S.: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 153
TABLE 61 U.S.: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 154
TABLE 62 U.S.: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 155
TABLE 63 U.S.: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 156
TABLE 64 U.S.: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 157
TABLE 65 U.S.: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 158
TABLE 66 CANADA: DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 161
TABLE 67 CANADA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 162
TABLE 68 CANADA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 163
TABLE 69 CANADA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 164
TABLE 70 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 165
TABLE 71 CANADA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 166
TABLE 72 CANADA: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 167
TABLE 73 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 168
TABLE 74 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 169
TABLE 75 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 170
TABLE 76 MERGERS and ACQUISITIONS, 2011 -2013 173
TABLE 77 AGREEMENTS, COLLABORATIONS, JOINT VENTURES and PARTNERSHIPS, 2011 -2013 176
TABLE 78 NEW PRODUCT LAUNCH, 2010 - 2012 178
TABLE 79 OTHER DEVELOPMENTS, 2010 - 2013 179
TABLE 80 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION) 189
TABLE 81 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION) 190
TABLE 82 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 201
TABLE 83 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE,
2010 - 2012($MILLION) 201
TABLE 84 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 202
TABLE 85 BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 206
TABLE 86 BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE,
BY SEGMENT, 2010 - 2012 ($MILLION) 207
TABLE 87 BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012($MILLION) 207
TABLE 88 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE, BY SEGMENT,
2009 - 2011 ($MILLION) 213
TABLE 89 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,
BY SEGMENT, 2010 - 2012 ($MILLION) 221
TABLE 90 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,
BY GEOGRAPHY, 2010 - 2012 ($MILLION) 222
TABLE 91 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 227
TABLE 92 JOHNSON and JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 233
TABLE 93 JOHNSON and JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 233
TABLE 94 THE DOW CHEMICAL COMPANY: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 252
TABLE 95 VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 258


LIST OF FIGURES


FIGURE 1 NORTH AMERICA DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (2012) 30
FIGURE 2 DRUG DELIVERY MARKET SEGMENTATION 34
FIGURE 3 MARKET DYNAMICS 37
FIGURE 4 PORTER'S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET 49
FIGURE 5 VALUE CHAIN ANALYSIS 52
FIGURE 6 U.S. PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 54
FIGURE 7 CANADA PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 55
FIGURE 8 U.S. TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 56
FIGURE 9 CANADA TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 57
FIGURE 10 U.S. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY KEY PLAYERS, 2012 58
FIGURE 11 CANADA INJECTABLE DRUG DELIVERY DEVICES MARKET,
BY KEY PLAYERS, 2012 60
FIGURE 12 U.S. IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 61
FIGURE 13 CANADA IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 62
FIGURE 14 OPPORTUNITY MATRIX: NORTH AMERICA DRUG DELIVERY MARKET (2012) 68
FIGURE 15 ORAL DRUG DELIVERY MARKET SHARE (2012) 71
FIGURE 16 KEY GROWTH STRATEGIES, 2010 - 2013 171
FIGURE 17 3M COMPANY: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($MILLION) 188
FIGURE 18 APTALIS PHARMA, INC.: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($MILLION) 195
FIGURE 19 BAXTER INTERNATIONAL: TOTAL REVENUE AND RandD EXPENSES,
2010 - 2012 ($MILLION) 200
FIGURE 20 BECTON, DICKINSON: TOTAL REVENUE AND RandD EXPENDITURE,
2010 - 2012 ($MILLION) 206
FIGURE 21 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE AND RandD EXPENSES, 2009 - 2011 ($MILLION) 213
FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 220
FIGURE 23 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 226
FIGURE 24 JOHNSON and JOHNSON, INC.: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 232
FIGURE 25 NEKTAR THERAPEUTICS, INC.: TOTAL REVENUE AND RandD EXPENSES, 2009 - 2011 ($MILLION) 239
FIGURE 26 PSIVIDA CORPORATION: TOTAL REVENUE, 2009 - 2011 ($MILLION) 247
FIGURE 27 THE DOW CHEMICAL COMPANY: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 252
FIGURE 28 VALEANT PHARMACEUTICALS: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 258


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The North American drug delivery technologies market is projected to reach USD 758.7 billion by 2021 from USD 520.0 billion in 2016, at a CAGR of 6.5% during the forecast period. Major factors contributing ...

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The syringes market is expected to reach USD 15.99 billion by 2021, at a CAGR of 8.7% from 2016 to 2021. The syringes market is primarily driven by the high prevalence of chronic diseases across the globe. ...

Injectable Drug Delivery Market Analysis, By Device Type, By Formulation, By Therapeutic Use, By End-user Application, By Region And Segment Forecasts From 2013 to 2024

Injectable Drug Delivery Market Analysis, By Device Type, By Formulation, By Therapeutic Use, By End-user Application, By Region And Segment Forecasts From 2013 to 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The global injectable drug delivery market is expected to reach USD 931.1 billion by 2024, according to a new report by Grand View Research, Inc. The increase in number of chronic diseases like diabetes ...

Drug Injection Devices To 2024

August 2016 $ 3850

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.